OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 11, 2023
This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility.
The definitive agreement will give AstraZeneca global rights to CinCor’s portfolio of cardiorenal disease treatments.
Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.
Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.
January 10, 2023
Eisai’s Alzheimer’s treatment, Leqembi (lecanemab-irmb), received approval from FDA via the Accelerated Approval pathway.
January 09, 2023
Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.
January 04, 2023
Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.
Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.
December 20, 2022
FDA has announced that bebtelovimab is not currently authorized for emergency use in any region of the US.
Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.